TCGA-AN-A0XP-01A-11R-A109-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.730
- PROTEIN_SECRETION+0.430
- INTERFERON_GAMMA_RESPONSE+0.390
- NOTCH_SIGNALING+0.380
- ANGIOGENESIS+0.240
- ESTROGEN_RESPONSE_EARLY+0.230
- APOPTOSIS+0.180
- HEME_METABOLISM+0.170
- TGF_BETA_SIGNALING+0.170
- CHOLESTEROL_HOMEOSTASIS+0.160
Top 10 suppressed
- E2F_TARGETS-0.490
- MYC_TARGETS_V2-0.400
- ALLOGRAFT_REJECTION-0.390
- G2M_CHECKPOINT-0.390
- MYC_TARGETS_V1-0.390
- MYOGENESIS-0.260
- SPERMATOGENESIS-0.260
- KRAS_SIGNALING_DN-0.240
- APICAL_JUNCTION-0.210
- IL6_JAK_STAT3_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1XY-01A-11R-A14M-07 | — | A | 0.781 |
| 2 | 20030031.LumA | — | A | 0.761 |
| 3 | TCGA-86-8278-01A-11R-2287-07 | — | cohortA1 | 0.697 |
| 4 | TCGA-A2-A0YC-01A-11R-A109-07 | — | B | 0.690 |
| 5 | SRR25617898 | — | A | 0.681 |
| 6 | TCGA-ZF-A9R3-01A-11R-A38B-07 | — | — | 0.678 |
| 7 | DRR168515 | — | — | 0.678 |
| 8 | TCGA-E9-A1RD-01A-11R-A157-07 | — | B | 0.675 |
| 9 | TCGA-E2-A10E-01A-21R-A10J-07 | — | B | 0.672 |
| 10 | TCGA-71-8520-01A-11R-2403-07 | — | cohortA1 | 0.661 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.730 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |